Table I.
Patient characteristics at time of diagnosis with bone metastases (n=236).
| Parameter | n (%) |
|---|---|
| Marital status | |
| Married/partner | 176 (75) |
| Single | 51 (22) |
| Unknown | 9 (4) |
| Residence | |
| Bodøa | 112 (48) |
| Surrounding communitiesb | 124 (53) |
| Charlson comorbidity index | |
| 0 | 109 (46) |
| 1 | 68 (29) |
| 2 | 31 (13) |
| >2 | 15 (6) |
| Unknown | 13 (6) |
| Gleason score | |
| ≥8 | 100 (42) |
| <8 | 83 (35) |
| Unknown | 53 (23) |
| NCCN risk category at first cancer diagnosis | |
| M1 | 81 (34) |
| N1 | 13 (6) |
| High | 97 (41) |
| Intermediate | 24 (10) |
| Unknown | 21 (9) |
| Initial treatment strategy | |
| Surgical treatment | 14 (6) |
| Radiotherapy ± endocrine treatment | 14 (6) |
| LHRH agonist | 116 (49) |
| Antiandrogen | 23 (10) |
| Orchiectomy | 10 (4) |
| Watchful waiting | 59 (25) |
| Bone metastases (isotope bone scan) | |
| 1 | 18 (8) |
| 2–4 | 52 (22) |
| 5–10 | 50 (21) |
| >10 or super scan | 99 (42) |
| Unknown | 17 (7) |
a
~50,000 inhabitants
b
~70,000 inhabitants. NCCN, National Comprehensive Cancer Network; LHRH, luteinizing hormone-releasing hormone.